A Phase I study of the novel ribonucleotide reductase inhibitor 3-aminopyridine-2-carboxaldehyde thiosemicarbazone (3-AP, Triapine®) in combination with the nucleoside analog fludarabine for patients with refractory acute leukemias and aggressive myeloproliferative disorders

Publication | Open Access

DOI Full Paper Access

Citations

References

2007

Year

Judith E. Karp, Francis J. Giles, Ivana Gojo, Lawrence E. Morris, Jacqueline M. Greer, Bonny Johnson, Mya Thein, Mario Sznol, Jennifer A. Low

Leukemia Research

Hematological MalignancyOncologyNucleoside Analog FludarabineMedicineAggressive Myeloproliferative DisordersHematologyPharmacotherapyAnti-cancer AgentPharmacologyRefractory Acute LeukemiasDrug DiscoveryMyeloid Neoplasia